Lenvatinib shows potential in advanced liver cancer

Lenvatinib may become a potential therapeutic option for patients with advanced hepatocellular carcinoma (HCC), the results of phase I/II clinical trial suggest.

Hepatocellular carcinoma: potential treatment identified (photo: SPL)

The findings were presented at the 2012 meeting of the European Society of Medical Oncology in Vienna this month.

Lenvatinib, an orally active inhibitor of multiple receptor tyrosine kinases (RTKs) involved in angiogenesis and tumour proliferation, is being investigated for the treatment of recurrent glioblastoma and in combination with everolimus in metastatic renal carcinoma.

The scope of the phase I/II clinical trial was to establish the safety and efficacy of lenvatinib in patients with advanced HCC.

Forty-six patients were enrolled in the trial; they may have had prior treatment for their HCC including sorafenib. The starting dose of lenvatinib was 12mg once daily in 28 days cycles until disease progression or progression of unmanageable toxicities.

The researchers observed that 76% patients required dose adjustments for the management of toxicities (hypertension, palmo-plantar erythrodysaesthesia syndrome, anorexia, proteinuria, fatigue and thrombocytopenia).

They concluded that, although in this study there were no new toxicities associated with TKI class, a weight-based starting dose of 8mg once daily for patients weighing under 60kg may be needed to minimise toxicity while maintaining the 12mg once daily for patients weighing over 60kg.

The median time to progression (TTP) is 7.49 months (95% CI:5.45-9.43) and media overall survival is 13.9 months (95% CI:11.8-).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Labour shadow health secretary Wes Streeting

Labour plans neighbourhood walk-in GP centres open seven days a week

Labour would set up new neighbourhood walk-in GP hubs that could be open seven days...

Scotland's cabinet secretary for health and social care Michael Matheson

Primary care will need bigger share of NHS funding in future, Scottish health secretary says

The share of NHS funding that goes to primary care will have to increase if the health...

Sign pointing to hospital

NHS England seeks to clarify GPs' responsibilities when using advice and guidance

New guidance from NHS England has set out the clinical responsibilities and medicolegal...

Widespread joint pain - red flag symptoms

Presentations and red flag symptoms that may alert you to potentially serious conditions...

Talking General Practice logo

Podcast: Supporting neurodivergent doctors and staff in general practice

Talking General Practice speaks to GPs Dr Beckie Akroyd and Dr Catherine Bell about...

BMA Scotland GP committee chair Dr Andrew Buist

General practice in Scotland 'in serious trouble', warns BMA Scotland GP chair

General practice in Scotland has reached a tipping point, with demand far outstripping...